论文部分内容阅读
目的探讨可溶性细胞间粘附分子-1(sICAM-1)在慢性乙型肝炎(简称乙肝)、乙肝肝硬化及原发性肝癌患者血清中的表达及其意义。方法选择慢性乙肝及其相关性肝病患者225例为研究对象,按照不同临床类型分为5组:自然痊愈组(66例)、无症状HBV携带组(22例)、慢性乙肝组(65例)、乙肝肝硬化组(失代偿或代偿肝硬化)(28例)和原发性肝癌组(51例);另选24名健康体检者作为正常对照组,利用ELISA法对5组患者及对照组血清sICAM-1水平进行测定。结果慢性乙肝组血清中sICAM-1水平(910±210)μg/L,明显高于正常对照组(567±107)μg/L(t=4.172,P<0.01);原发性肝癌组血清中sICAM-1水平(1179±541)μg/L,明显高于慢性乙肝组(t=3.208,P<0.01);乙肝肝硬化组血清中sICAM-1水平(1906±682)μg/L,明显高于原发性肝癌组(t=4.084,P<0.01)。自然痊愈组血清sICAM-1水平(594±348)μg/L及无症状携带组血清sICAM-1水平(570±181)μg/L与正常对照组比较差异均无统计学意义(P>0.05)。结论慢性乙肝及乙肝相关性肝病患者sICAM-1的表达均升高,这可作为临床乙肝活动和乙肝相关性肝病损害的指标。
Objective To investigate the expression of soluble intercellular adhesion molecule-1 (sICAM-1) in serum of patients with chronic hepatitis B (HBV), hepatitis B cirrhosis and primary liver cancer and its significance. Methods Totally 225 patients with chronic hepatitis B and its related liver diseases were divided into five groups according to different clinical types: natural recovery group (66 cases), asymptomatic HBV carrier group (22 cases) and chronic hepatitis B group (65 cases) , Liver cirrhosis (decompensated or compensated cirrhosis) (28 cases) and primary liver cancer group (51 cases); another 24 healthy subjects were selected as normal control group, The control group serum sICAM-1 levels were measured. Results Serum levels of sICAM-1 in chronic hepatitis B group were significantly higher than those in normal control group (910 ± 210 μg / L vs 567 ± 107 μg / L, t = 4.172, P <0.01) The level of sICAM-1 in serum of patients with hepatitis B cirrhosis (1906 ± 682 μg / L) was significantly higher than that of chronic hepatitis B patients (1179 ± 541 μg / L, t = 3.208, In the primary liver cancer group (t = 4.084, P <0.01). The serum sICAM-1 levels (594 ± 348) μg / L and sICAM-1 levels (570 ± 181) μg / L in asymptomatic carriers of natural recovery group were not significantly different from the normal control group (P> 0.05) . Conclusion The expression of sICAM-1 is increased in patients with chronic hepatitis B and hepatitis B-related liver diseases, which may be used as indicators of clinical hepatitis B activity and hepatitis B-related liver damage.